Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSY-PGx pharmacogenetic-guided prescribing in psychiatry
NL-OMON57758Active, not recruiting
- Sponsor
- Maastricht University
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sertraline, escitalopram, aripiprazole and risperidone in major depressive disorder (MDD), bipolar disorder (BD), panic disorder and 3 more (2 arms), sponsored by Maastricht University. Primary endpoint: Clinical recovery. Started Feb 2023; status: active, not recruiting.
02
Drugs
sertralineescitalopramaripiprazolerisperidone
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)panic disordergeneralized anxiety disorder (GAD)schizophrenia
Beyond the preview
Go deeper on NL-OMON57758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57758.